Citation:Van Andel G, Kurth KH, Rietbroek RL, van De Velde-Muusers JA 2000

Citation

van Andel G, Kurth KH, Rietbroek RL, van De Velde-Muusers JA. Quality of life assessment in patients with hormone-resistant prostate cancer treated with epirubicin or with epirubicin plus medroxy progesterone acetate - is it feasible? Eur Urol 2000 Sep;38(3):259-64 Available from: http://www.ncbi.nlm.nih.gov/pubmed/10940698.

Critical appraisals

• Assign a critical appraisal

Cited by

1. Is any one hormone therapy (androgen ablation) superior to another when given in the first line setting in terms of survival in metastatic disease?